Zevra Therapeutics (ZVRA) Stock Analysis: AI Score & Alternative Data
Demand signals are heating up for Zevra Therapeutics
Is Zevra Therapeutics a buy right now? The alternative data says hold. This ZVRA stock analysis is built on the 25+ alternative data signals AltIndex tracks on Zevra Therapeutics every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 50/100: a Hold. The stock trades at $10.27 with a $607M market cap.
The data leans positive over the past 90 days — revenue up 33.3% YoY to $40M, and web traffic up 30.8% to 17K monthly visits — but the move hasn’t been broad enough to lift ZVRA into buy territory yet.
ZVRA’s broader alt-data profile also covers job postings (10 open roles), headcount (78 employees, according to LinkedIn), X followers (790), and sentiment (100/100). Every signal links to its own page with full history, the ZVRA technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on ZVRA is just below.
Zevra Therapeutics AI Stock Analysis
Zevra Therapeutics is a forward-thinking biopharmaceutical company focused on the development and commercialization of treatments for rare diseases. The company is known for its innovative approach to drug development and its commitment to addressing unmet medical needs.
Analysis generated October 4, 2026.
Recent Zevra Therapeutics Stock Alerts
|
Zevra Therapeutics | October 15 Insider Alert: McFarlane Neil F. is selling shares |
|
Zevra Therapeutics | October 13 Price is down by -6% in the last 24h. |
|
Zevra Therapeutics | October 5 Price is up by 7.1% in the last 24h. |
|
Zevra Therapeutics | October 1 Price is down by -6.1% in the last 24h. |
Zevra Therapeutics Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 17K | 30.8% | |
| Job Posts | 10 | 0% | |
| LinkedIn Employees | 78 | 4.9% | |
| Sentiment | 100 | 0% | |
| Reddit Mentions | 0 | N/A | |
| X Mentions | 1 | 0% | |
| Stocktwits Mentions | 50 | 29.6% | |
| News Mentions | 0 | N/A | |
| Stocktwits Subscribers | 24K | 0% | |
| 4chan Mentions | 0 | N/A | |
| X Followers | 790 | 1.2% |
About Zevra Therapeutics (ZVRA)
Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States.
| Price | $10.27 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $607M |
| Year Range | $8 – $15 |
| Dividend Yield | 0% |
| PE Ratio | 11.1 |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest Zevra Therapeutics News
View more →
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRAAugust 4 - GlobeNewswire |
|
Zevra Therapeutics to Present at the Canaccord Genuity Annual Growth ConferenceAugust 4 - GlobeNewswire |
|
 |
Zevra Therapeutics (ZVRA) Securities Investigation Notice - Levi & KorsinskyAugust 3 - PRNewswire |
Zevra Therapeutics Announces Publication of Four-Year Real-World Data from U.S. Early Access Program Evaluating MIPLYFFA® (arimoclomol) in Niemann-Pick Disease Type C (NPC)August 3 - GlobeNewswire |
|
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Zevra Therapeutics (ZVRA)July 30 - GlobeNewswire |
|
See Zevra Therapeutics’s complete price and AI Score history
Sign up to unlock 1-year and all-time charts for ZVRA, plus 25+ alternative data signals, AI Scores, and real-time alerts.
Get Started for FREEZevra Therapeutics Earnings & Financial Performance
View all earnings →Zevra Therapeutics Insider Trading Activity
View all →| McFarlane Neil F. filed to sell 417,225 shares at $0.0. Oct 12 '26 |
| Thompson Rahsaan filed to sell 37,569 shares at $0.0. Aug 14 '26 |
| Watton Corey Michael filed to sell 1,800 shares at $0.0. Aug 10 '26 |
| Thompson Rahsaan filed to sell 80,235 shares at $0.0. Jun 22 '26 |
| Thompson Rahsaan filed to sell 48,125 shares at $0.0. May 11 '26 |
Zevra Therapeutics Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to Zevra Therapeutics
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
ProKidneyPROK |
$1.46 1.0% | $607M | 46 |
 |
Sophia Genetics SASOPH |
$7.29 3.3% | $601M | 55 |
 |
Solid BiosciencesSLDB |
$5.74 5.0% | $615M | 46 |
 |
Arbutus BiopharmaABUS |
$4.29 2.4% | $630M | 46 |
 |
Prime MedicinePRME |
$3.61 15.3% | $568M | 60 |
Explore Zevra Therapeutics Data
Frequently Asked Questions: Zevra Therapeutics (ZVRA)
Zevra Therapeutics has an AltIndex AI Score of 50/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
50/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Zevra Therapeutics (ZVRA) stock is $10.27 with a market cap of $607M.
As of today, Zevra Therapeutics’s PE (Price to Earnings) ratio is 11.1.
View the latest Zevra Therapeutics insider transactions to see recent buying and selling activity by company executives and directors.
Check the Zevra Therapeutics congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The ZVRA stock price chart above shows Zevra Therapeutics’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Zevra Therapeutics technical analysis for RSI, moving averages, and more.
See the stocks similar to Zevra Therapeutics section on this page for companies in the same industry ranked by market cap and AI Score.
